AI can predict how early breast cancer patients might respond to their treatments
Durham University - 09-Feb-2024This could lead to more personalised treatment plans and better outcomes
Join the club for FREE to access the whole archive and other member benefits.
One of the world’s most influential cancer research organizations
The ICR is led by Chief Executive Professor Kristian Helin — known for his pioneering scientific discoveries in cancer epigenetics.
We are world leaders in identifying cancer genes, discovering cancer drugs and developing precision radiotherapy.
Together with our hospital partner The Royal Marsden NHS Foundation Trust, we are rated as one of the top centres for cancer research and treatment worldwide.
As well as being as world-class research institute, the ICR is a higher education institution and a member institution of the University of London. We came top in the league table of university research quality compiled from the Research Excellence Framework (REF 2014).
Visit website: https://www.icr.ac.uk/
the-institute-of-cancer-research
Details last updated 04-Feb-2019
Consultant Clinical Oncologist and Professor specializes in Biological Cancer Therapies, head and neck cancer, immunotherapy
Head of the Division of Cancer Therapeutics, Institute of Cancer Research and Royal Marsden Hospital.
Team Leader of Gastrointestinal Cancer Biology and Genomics at The Institute Of Cancer Research.
Professor of Cancer Genomics & Evolution and Deputy Director of the Centre for Evolution and Cancer.
This could lead to more personalised treatment plans and better outcomes
Potential to fast-track patients to treatment and streamline CT scan analysis
Capivasertib could become a game-changer for advanced breast cancer patients
Early but promising finding that epigenetic changes alter the growth of cancer cells
Weakened form of herpes virus showed promising results for various advanced cancers
Precisely targeted therapy shrank tumours and extends life by 38% in men
Indeed a new precision approach sparing healthy cells
A safer and more immune-friendly precision-medicine approach for cancer
Partnering with Japan's DSP, a milestone is reached in OCD treatment
Improving effectiveness with reduced side effects - fingers crossed for this first-in-person trial
Only 5% saw their tumours shrink, but may be more successful if used earlier
Needs to identify those who will respond to treatment before starting immunotherapy
Olaparib delays cancer growth by months, which means the increased lifespan
By determining the DHX8's structure, scientists could discover new ways of cancer treatment
Cancer targeted first, but could clear out age-related proteins in future
Novel mechanisms for attacking cancer cells are always good news
Once trained artificial intelligence is almost aways going to be more reliable than humans
Biopsies were taken and grown into miniature 3D cancerous organs in the lab. 100% accurate at te...
Highly targeted form of radiotherapy shapes radiation beams to tumours. When prostate cancer has...
DNA mutation of individual tumour analysed when removed. Regular tests then searched for unique D...
Study finds prostate cancer is not one disease but several – enabling personalised treatments usi...